Filing Details

Accession Number:
0001209191-23-044534
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-08-03 18:03:20
Reporting Period:
2023-08-01
Accepted Time:
2023-08-03 18:03:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1671858 Ars Pharmaceuticals Inc. SPRY () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1551891 Laura Shawver C/O Ars Pharmaceuticals, Inc.
11682 El Camino Real, Suite 120
San Diego CA 92130
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-08-01 18,715 $1.27 229,061 No 4 M Direct
Common Stock Disposition 2023-08-01 18,715 $7.19 210,346 No 4 S Direct
Common Stock Acquisiton 2023-08-02 36,281 $1.27 246,627 No 4 M Direct
Common Stock Disposition 2023-08-02 36,281 $7.09 210,346 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-08-01 18,715 $0.00 18,715 $1.27
Common Stock Stock Option (Right to Buy) Disposition 2023-08-02 36,281 $0.00 36,281 $1.27
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
84,282 2030-04-28 No 4 M Direct
48,001 2030-04-28 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.11 to $7.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.95 to $7.23, inclusive. The Reporting Person undertakes to provide the the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
  4. Immediately exercisable.